Stroke and Headache Headache and Stroke

Size: px
Start display at page:

Download "Stroke and Headache Headache and Stroke"

Transcription

1 Stroke and Headache Headache and Stroke Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Tobias Kurth Institute of Public Health Charité Universitätsmedizin Berlin Germany

2 Conflict of Interest Statement (Headache) German Research Council German Ministry of Education and Reserach EU Addex Alder Allergan Almirall Amgen Astra-Zeneca Bayer BMS Böhringer-Ingelheim Chordate Coherex CoLucid Eisai Electrocore Endo Pharmac. GSK Janssen-Cilag J&J Labrys Lilly MAP Menarini Medtronic MSD Neuroscore Novartis Novo Nordisk Pfizer Sanofi-Aventis Schering Solvay St. Jude Medical Teva Weber & Weber Wyeth

3 Conflict of Interest Statement (Stroke) The speaker or his institution received financial support from the following bodies or companies: German Research Council German Ministry of Health German Ministry of Science and Technology European Union Bertelsmann Foundation Heinz-Nixdorf Foundation Abbott Allergan Achelios Actelion AstraZeneca Bayer Boehringer Ingelheim Brainsgate BristolMyersSquibb CoAxia Corimmun Covidien D-Pharm Daiichi-Sankyo Fresenius GlaxoSmithKline Jansen-Cilag Johnson&Johnson Lilly Lundbeck Medtroni Mindframe MSD Neurobiological Technologies Novo Nordisk Novartis Paion Pfizer Sanofi Schering Schering Plough Servier Solvay St. Jude Syngis Tacrelis Thrombogenics

4 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimics Here is the summary and conclusion 4

5 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 5

6 Headache in Stroke 6

7 Headache in Stroke 7

8 Headache associated with ischemic stroke Presentation and course Onset abrupt or gradual More frequent in posterior circulation strokes More severe in basilar artery stroke Sentinel headache only in SAH Late onset associated with brain edema 8

9 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 9

10 Schlaganfall und Kopfschmerzen Lesions were summed 10

11 Schlaganfall und Kopfschmerzen Involvement of the central pain network 11

12 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 12

13 Epidemiologic evidence: migraine-stroke First description of migrainous infarct likely by Charcot and Féré ~1883 Several clinic- and population-based studies found an association between migraine and increased risk of ischemic stroke Consistent findings from cross-sectional, casecontrol, and cohort studies Particular increased risk for younger women (<45 years) Most studies found increased risk of stroke only among migraineurs with aura

14 Epidemiologic evidence: migraine-stroke, cont. Findings from prospective cohort studies: Atherosclerosis Risk in Communities Study (ARIC) included 12,409 men and women mostly aged >55* Migraine/headache assessed via interview Medical record validated strokes Women s Health Study (WHS) included 39,754 women aged >45 and free of cardiovascular disease ** Migraine/headache self-reported Medical record confirmed stroke * Stang et al. Neurology 2005; 64: ** Kurth et al. Neurology 2005; 64:1020-6

15 Relative Risk Epidemiologic evidence: migraine-stroke, cont. Association between migraine/headache and ischemic stroke 2,5 2,0 1,5 1,0 Migraine + aura Migraine - aura Non-migraine headache 0,5 0,0 ARIC* WHS** Risk of stroke increased in migraine with aura * Stang et al. Neurology 2005; 64: ** Kurth et al. Neurology 2005; 64:1020-6

16 Migraine and stroke: meta-analysis Case-control and cohort studies included 9 studies evaluated association between migraine and ischemic stroke from different source populations If studies uses same underlying source population, only longest follow-up or cohort design was selected Overall migraine associated with 70% increased risk of ischemic stroke (RR=1.73; 95% CI= ) Association only apparent among migraineurs with aura Schürks et al. BMJ 2009;339:b3914

17 Migraine and stroke: meta-analysis, cont. Association between migraine with and without aura and ischemic stroke Risk of stroke increased in migraine with aura Schürks et al. BMJ 2009;339:b3914

18 Relative Risk Migraine and stroke: meta-analysis subgroups Relative Risk of Ischemic Stroke Overall MA MO Women <45 + OC + Smoking Most important risk factors: oral contraception and smoking Schürks et al. BMJ 2009;339:b3914

19 Migraine and hemorrhagic stroke Migraine with aura increased the risk of hemorrhagic stroke RR = 2.31 ( ) Kurth et a. BMJ 2010;c3659

20 Relatives Risko Migraine and hemorrhagic stroke Adjusted Relative Risk 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 Hem. Stroke ICH SAH Fatal MA Migraine increases the risk of intracranial hemorrhage Kurth et a. BMJ 2010;c3659

21 Epidemiology Migraine is a risk factor for any vascular disease 21

22 Migraine and perioperative stroke Risk of stroke within 30 days of surgery (N= ) 22

23 Migraine and perioperative stroke Risk of perioperative ischemic stroke increased by 75% 23

24 CT and CT angiography 24

25 No increased risk of atherosclerosis in patients with migraine and stroke 25

26 Summary Migraine with aura is a risk factor for ischemic stroke Migraine is a risk factor for cerebral hemorrhage Migraine with aura is a risk factor for vascular diseases Migraine increases the risk of perioperative stroke Patients with migraine have more vascular risk factors (but not more atherosclerosis) Patients with migraine might have dysfunction of the endothelium 26

27 Migraine genetics 27

28 Migraine genetics The new gene loci code for vascular endothelium, CNS pain structures, GI tissue and smooth muscle 28

29 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 29

30 Migraine and structural brain lesions Several studies have linked migraine with increased load of white matter lesions and increase in infarctlike lesions in the posterior circulation The CAMERA study showed: Migraine associated with 7-fold increase in risk of infarctlike lesions in cerebellum with migraine frequency and among migraine with aura In women, migraine with aura doubled risk of deep WML No difference according to migraine aura status Reykjavik study showed: Migraine with aura in midlife increased infarct-like lesions the cerebellum in late-life by 60% Result only apparent among women (RR = 1.9)

31 % with High-DWML-load Deep WML in migraine patients The Dutch CAMERA general population MRI study 35,0 30,0 25,0 20,0 15,0 10,0 5,0 0, Quintiles of attack frequency Migraineurs (n=195) Controls (n=140) Effect attacka frequency in women < 50 yr 1 Controls 4,6 p<0.03 Migraine <1/month 7,8 p<0.005 Migraine >1/month Kruit MC, et al. JAMA 2004; 291:

32 Migraine, white matter lesions and silent brain infarcts 32

33 Migraine, white matter lesions and silent brain infarcts No increase in white matter lesions and silent brain infarcts in migraine with aura 33

34 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 34

35

36

37 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 37

38 Migraine with aure and patent foramen ovale (PFO) PFO occlusion not effective to prevent migraine with aura 38

39 Summary Conflicting data concerning white matter lesions and silent brain infarcts in migraine with aura Migraine is a risk factor for dissection PFO closure does not prevent migraine with aura 39

40 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 40

41 a Headache in combination with prolonged reversible neurological signs 41

42 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimcs 42

43 a Headache frequent symptom 43

44 a Triggers or associations with PRES Autoimmune disorders Systemic LE TTP Scleroderma Crohn s disease Rheumatoid arthritis Immunosuppressive or cytotoxic drugs Ciclosporine Tacrolimus Antiangiogenic drugs Triggers or associations with PRES Renal failure Hypertensive crisis Low magnesium Pregnancy Headache frequent symptom 44

45 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimics 45

46 a 46

47 Overview Headache in stroke Pathophysiology of headache in stroke Epidemiology of stroke and migraine Migraine and structural brain lesions Migraine and arterial dissection Migraine and PFO SMART Posterior reversible encephalopathy syndrome Stroke mimics 47

48 Thank you

Clinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany

Clinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany Clinical Trials Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany Conflict of Interest Statement German Research Council German Ministry

More information

New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy

New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest

More information

Editorial Team Conflict of Interest Statements

Editorial Team Conflict of Interest Statements Editorial Team Conflict of Interest Statements Editor in Chief David Dodick Advisory board/consultant: Allergan, Amgen, Alder, Arteaus, Pfizer, Colucid, Merck, ENeura, NuPathe, Eli Lilly, Autonomic Technologies,

More information

Migraine and Stroke: What s the link? Christine Lay, MD, FAHS Associate Professor (Neurology) University of Toronto Director, Headache

Migraine and Stroke: What s the link? Christine Lay, MD, FAHS Associate Professor (Neurology) University of Toronto Director, Headache Migraine and Stroke: What s the link? Christine Lay, MD, FAHS Associate Professor (Neurology) University of Toronto Director, Headache Disclosures Objectives Consultant Novartis, Aralez Research/educational

More information

PFO Closure for the Management of Migraine and Stroke

PFO Closure for the Management of Migraine and Stroke PFO Closure for the Management of Migraine and Stroke Sun U. Kwon Department of Neurology, Asan Medical Center, UUMC Contents PFO & Migraine PFO causes Migraine or Not? PFO closure for Migraine PFO & Stroke

More information

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,

More information

Funding Wellcome Trust, the National Institute of Health Research (NIHR) Biomedical Research Centre, Oxford.

Funding Wellcome Trust, the National Institute of Health Research (NIHR) Biomedical Research Centre, Oxford. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials Peter M Rothwell, Ale Algra, Zhengming

More information

Update on clopidogrel and dual anti-platelet therapy: neurology

Update on clopidogrel and dual anti-platelet therapy: neurology European Heart Journal Supplements (2006) 8 (Supplement G), G15 G19 doi:10.1093/eurheartj/sul049 Update on clopidogrel and dual anti-platelet therapy: neurology Hans-Christoph Diener Department of Neurology,

More information

Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database

Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database doi:10.1111/j.1468-2982.2007.01457.x Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database H-C Diener 1, DW Dodick 2, PJ Goadsby 3, RB Lipton 4, M

More information

7 th Munich Vascular Conference

7 th Munich Vascular Conference 7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.

More information

Migraine and Patent Foramen Ovale (PFO)

Migraine and Patent Foramen Ovale (PFO) Migraine and Patent Foramen Ovale (PFO) Hans-Christoph Diener Senior Professor of Clinical Neurosciences Department of Neurology and Headache Center University Essen Topics Prevalence of PFO Is migraine

More information

Decision for fibrinolysis or primary PCI in the prehospital phase

Decision for fibrinolysis or primary PCI in the prehospital phase Decision for fibrinolysis or primary PCI in the prehospital phase Nicolas Danchin, Hôpital Européen Georges Pompidou, Paris, France Disclosures Research grants: Astrazeneca, Eli-Lilly, GSK, Merck, Novartis,

More information

Home Time Is Extended in Patients With Ischemic Stroke Who Receive Thrombolytic Therapy A Validation Study of Home Time as an Outcome Measure

Home Time Is Extended in Patients With Ischemic Stroke Who Receive Thrombolytic Therapy A Validation Study of Home Time as an Outcome Measure Home Time Is Extended in Patients With Ischemic Stroke Who Receive Thrombolytic Therapy A Validation Study of Home Time as an Outcome Measure Nishant K. Mishra, MBBS; Ashfaq Shuaib, MD; Patrick Lyden,

More information

Novel Anticoagulants : Bleeding and Bridging

Novel Anticoagulants : Bleeding and Bridging Novel Anticoagulants : Bleeding and Bridging Michael D. Ezekowitz, MBChB, DPhil, FACC, FAHA, FRCP, MA Professor, Thomas Jefferson Medical School Director Atrial Fibrillation Research and Education The

More information

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.

More information

Engage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom

Engage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor

More information

The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension

The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension Michael Böhm, MD on behalf of the GSR Investigators March 30,

More information

WHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France.

WHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France. TAVI WITH ATRIAL FIBRILLATION: WHICH ANTITHROMBOTIC REGIMEN? G. MONTALESCOT (PARIS, FR) Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France www.action-cœur.org Dr. Montalescot

More information

INTRACEREBRAL HAEMORRHAGE:

INTRACEREBRAL HAEMORRHAGE: INTRACEREBRAL HAEMORRHAGE: WHAT IS THE CAUSE? Prof. Charlotte Cordonnier Head, Department of neurology & stroke centre Director, Lille haemorrhagic stroke research program Lille University Hospital France

More information

The Universal Definition of Myocardial Infarction 3 rd revision, 2012

The Universal Definition of Myocardial Infarction 3 rd revision, 2012 The Universal Definition of Myocardial Infarction 3 rd revision, 2012 Joseph S. Alpert, MD Professor of Medicine, University of Arizona College of Medicine, Tucson, AZ; Editor-in-Chief, American Journal

More information

Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger

Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,

More information

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic

More information

How clinically important are the results of the large trials in hypertension?

How clinically important are the results of the large trials in hypertension? How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université

More information

NT-proBNP For The Detection of Silent Paroxysmal Atrial Fibrillation In Patients With Recent Cerebral Ischemia results from the Find-AF trial

NT-proBNP For The Detection of Silent Paroxysmal Atrial Fibrillation In Patients With Recent Cerebral Ischemia results from the Find-AF trial NT-proBNP For The Detection of Silent Paroxysmal Atrial Fibrillation In Patients With Recent Cerebral Ischemia results from the Find-AF trial R. Wachter a, R. C. Lahno a, B. Haase a, M. Weber-Krüger a,

More information

This e-reprint is distributed with the support of Bayer Pharma / Bayer Vital

This e-reprint is distributed with the support of Bayer Pharma / Bayer Vital http://neurology.thelancet.com Reprint Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF Graeme

More information

PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE AND ATRIAL SEPTAL DEFECT: STATE OF THE ART AND A CRITICAL APPRAISAL

PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE AND ATRIAL SEPTAL DEFECT: STATE OF THE ART AND A CRITICAL APPRAISAL PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE AND ATRIAL SEPTAL DEFECT: STATE OF THE ART AND A CRITICAL APPRAISAL Carmelo Cernigliaro Clinica San Gaudenzio Novara Eco 2D e 3D Eco Transesofageo Large shunt

More information

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban

More information

The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging

The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging REBECCA F. GOTTESMAN, MD PHD ASSOCIATE PROFESSOR OF NEUROLOGY AND EPIDEMIOLOGY JOHNS HOPKINS UNIVERSITY OCTOBER 20, 2014 Outline

More information

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai. Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,

More information

Patent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS

Patent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS Patent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS 11-8-18 Outline 1. Background 2. Anatomy of patent foramen ovale (PFO) 3. Relationship between PFO and

More information

in patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017

in patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017 Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients with diabetes, nephropathy

More information

Antithrombotic therapy in the ACS patient with atrial fibrillation

Antithrombotic therapy in the ACS patient with atrial fibrillation Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,

More information

Should hypertensive disorders of pregnancy be considered as a prehypertension state?

Should hypertensive disorders of pregnancy be considered as a prehypertension state? February 2018 Should hypertensive disorders of pregnancy be considered as a prehypertension state? Pr. Jacques Blacher Paris-Descartes University ; AP-HP ; Unité HTA, prévention et thérapeutique cardio-vasculaires,

More information

J. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018

J. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018 ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.

More information

NOAC trials for AF: A review

NOAC trials for AF: A review NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter

More information

NOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich

NOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,

More information

CEREBRO VASCULAR ACCIDENTS

CEREBRO VASCULAR ACCIDENTS CEREBRO VASCULAR S MICHAEL OPONG-KUSI, DO MBA MORTON CLINIC, TULSA, OK, USA 8/9/2012 1 Cerebrovascular Accident Third Leading cause of deaths (USA) 750,000 strokes in USA per year. 150,000 deaths in USA

More information

Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan

Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan J Headache Pain (2008) 9:359 365 DOI 10.1007/s10194-008-0070-6 ORIGINAL Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan Hans-Christoph

More information

controversies in anticoagulation: optimizing outcome for atrial fibrillation

controversies in anticoagulation: optimizing outcome for atrial fibrillation controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT

More information

Per cent of patients with chronic migraine who responded per onabotulinumtoxina treatment cycle: PREEMPT

Per cent of patients with chronic migraine who responded per onabotulinumtoxina treatment cycle: PREEMPT Migraine 1 Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA 2 Department of Neurology, Mayo Clinic Arizona, Phoenix, Arizona, USA 3 Department of Neurology and Neurological

More information

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Disclosures Research contracts: AstraZeneca, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company,

More information

Why Treat Patent Forman Ovale

Why Treat Patent Forman Ovale Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural Heart Disease Rush University Medical Center Conclusions

More information

SUPPLEMENTARY DATA. Telediab Study Group :

SUPPLEMENTARY DATA. Telediab Study Group : Telediab Study Group : Guillaume Charpentier, MD, Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France Centre d Études et de Recherches pour l Intensification du Traitement du Diabète

More information

A Patient Unsuitable for VKA Treatment

A Patient Unsuitable for VKA Treatment Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following

More information

Post Hoc Analysis of the PARADIGM Heart Failure Trial:

Post Hoc Analysis of the PARADIGM Heart Failure Trial: Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming

More information

nephropathy and/or chronic kidney disease Summary of recommendations

nephropathy and/or chronic kidney disease Summary of recommendations July 2017 Guidelines: Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients

More information

Glucose Control and Prevention of Cardiovascular Disease

Glucose Control and Prevention of Cardiovascular Disease Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March

More information

Evidence grades for the recommendations

Evidence grades for the recommendations Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy

More information

ANTIPAF Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial

ANTIPAF Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial European Society of Cardiology Hotline Stockholm - Zone K 31 st August 2010 Placebo ARB Kumagai K, et al. JACC 2003 Discussant ANTIPAF Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial

More information

Clinical impact of practice registers in Bourgogne and Rhône Alpes

Clinical impact of practice registers in Bourgogne and Rhône Alpes Clinical impact of practice registers in Bourgogne and Rhône Alpes Dr Yannick Béjot The Dijon Stroke Registry EA4184, University Hospital and Medical School of Dijon, France Dr Carlos El KHOURY c.elkhoury@ch-vienne.fr

More information

SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI?

SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI? SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI? Kurt Huber, MD 3 Department of Internal Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria Disclosures DISCLOSURE

More information

Giancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group. Assessment of oral laquinimod in preventing progression of Multiple Sclerosis

Giancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group. Assessment of oral laquinimod in preventing progression of Multiple Sclerosis COMPARISON OF EARLY AND DELAYED ORAL LAQUINIMOD IN PATIENTS WITH RELAPSING- REMITTING MULTIPLE SCLEROSIS: EFFECTS ON DISABILITY PROGRESSION AT 36 MONTHS IN THE ALLEGRO TRIAL Giancarlo Comi, M.D. On Behalf

More information

Industry Relationships and Institutional Affiliations

Industry Relationships and Institutional Affiliations Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher

More information

Significant Relationships

Significant Relationships Opening Large Vessels During Acute Ischemic Stroke Significant Relationships Wade S Smith, MD, PhD Director UCSF Neurovascular Service Professor of Neurology Daryl R Gress Endowed Chair of Neurocritical

More information

ESC Heart & Brain Workshop

ESC Heart & Brain Workshop Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced

More information

Why Should We Treat PFO?

Why Should We Treat PFO? Why Should We Treat PFO? SCAI Interventional Cardiology Fellows Course December 7, 2012 Jonathan Tobis, MD Director of Interventional Cardiology UCLA Disclosures Jonathan Tobis, MD 1. A Principal Investigator

More information

Management of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil

Management of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,

More information

Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective

Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective Cathy Sila MD George M Humphrey II Professor and Vice Chair of Neurology Director, Comprehensive Stroke Center

More information

PRESCRIBING HORMONAL CONTRACEPTIVES TO WOMEN WITH MIGRAINE (CON) Disclosures. Objectives/Discussion Points 6/2/2017

PRESCRIBING HORMONAL CONTRACEPTIVES TO WOMEN WITH MIGRAINE (CON) Disclosures. Objectives/Discussion Points 6/2/2017 PRESCRIBING HORMONAL CONTRACEPTIVES TO WOMEN WITH MIGRAINE (CON) Gretchen E. Tietjen, MD Department of Neurology University of Toledo Disclosures Advisory Boards: Eli Lilly, Dr. Reddy s Common Stock: J&J,

More information

Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece

Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece Disclosures Scholarships: European Stroke Organization; Hellenic Society of Atherosclerosis.

More information

True cryptogenic stroke

True cryptogenic stroke True cryptogenic stroke Arne Lindgren, MD, PhD Dept of Clinical Sciences Lund, Neurology, Lund University Dept of Neurology and Rehabilitation Medicine Skåne University Hospital Lund, Sweden Disclosures

More information

CLOSE. Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence

CLOSE. Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence CLOSE Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence Guillaume TURC, MD, PhD Paris Descartes University Sainte-Anne hospital Paris, France On

More information

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn Letter Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, openlabel study J. Rosenstock 1,2,

More information

NAME CTS AFFILIATION DISCLOSURE UPDATED

NAME CTS AFFILIATION DISCLOSURE UPDATED NAME CTS AFFILIATION DISCLOSURE UPDATED Darcy Marciniuk (Chair) and Canadian and Canadian COPD Alliance Consultant Fee, Speaker s Bureau, Advisory Committee: AstraZeneca, Boehringer-Ingelheim, Canadian

More information

Modified-release dipyridamole combined with aspirin for secondary stroke prevention

Modified-release dipyridamole combined with aspirin for secondary stroke prevention For reprint orders, please contact: reprints@futuremedicine.com DRUG EVALUATION Modified-release dipyridamole combined with aspirin for secondary stroke prevention Hans-Christoph Diener University Essen,

More information

ASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes

ASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes ASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes Jane Armitage and Louise Bowman on behalf of the ASCEND

More information

Nicolas Bianchi M.D. May 15th, 2012

Nicolas Bianchi M.D. May 15th, 2012 Nicolas Bianchi M.D. May 15th, 2012 New concepts in TIA Differential Diagnosis Stroke Syndromes To learn the new definitions and concepts on TIA as a condition of high risk for stroke. To recognize the

More information

ESC Heart & Brain Workshop

ESC Heart & Brain Workshop ESC Heart & Brain Workshop The role of vascular surgeon in stroke prevention Barbara Rantner, MD, PhD, Department of Vascular Surgery, Medical University Innsbruck, Innsbruck, Austria Supported by Bayer,

More information

Sex Differences in Stroke Risk and Quality of Life after Stroke

Sex Differences in Stroke Risk and Quality of Life after Stroke Sex Differences in Stroke Risk and Quality of Life after Stroke Cheryl Bushnell, MD, MHS Associate Professor of Neurology Director, WFB Stroke Center Disclosures Research funding from: World Federation

More information

With the increasing use of MRI, cerebral white matter

With the increasing use of MRI, cerebral white matter Telmisartan on Top of Antihypertensive Treatment Does Not Prevent Progression of Cerebral White Matter Lesions in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) MRI Substudy Ralph

More information

MIGRAINE AFFECTS UP TO

MIGRAINE AFFECTS UP TO ORIGINAL CONTRIBUTION Scan for Author Video Interview Structural Brain Changes in Inge H. Palm-Meinders, MD Hille Koppen, MD Gisela M. Terwindt, MD, PhD Lenore J. Launer, PhD Junya Konishi, MD Juliette

More information

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma

More information

ESC Heart & Brain Workshop

ESC Heart & Brain Workshop ESC Heart & Brain Workshop Carotid Stenosis - selecting the high risk patients for intervention Alison Halliday, Professor of Vascular Surgery, University of Oxford 20 th January 2018, Prague ESC Workshop

More information

The HEMORR 2 HAGES, ATRIA and the HAS-BLED bleeding risk prediction scores in anticoagulated atrial fibrillation patients : The AMADEUS study

The HEMORR 2 HAGES, ATRIA and the HAS-BLED bleeding risk prediction scores in anticoagulated atrial fibrillation patients : The AMADEUS study The HEMORR 2 HAGES, ATRIA and the HAS-BLED bleeding risk prediction scores in anticoagulated atrial fibrillation patients : The AMADEUS study Apostolakis S 1, Lane DA 1, Buller H 2, Lip GY 1 1 University

More information

The impact of antiretroviral drugs on Cardiovascular Health

The impact of antiretroviral drugs on Cardiovascular Health The impact of antiretroviral drugs on Cardiovascular Health José López-Sendón Hospital Universitario La Paz. IdiPaz Madrid. Spain Research grants and honoraria from (research committees, clinical trials,

More information

Vague Neurological Conditions

Vague Neurological Conditions Vague Neurological Conditions Dr. John Lefebre, MD, FRCPC Chief Regional Medical Director Europe, India, South Africa, Middle East and Turkey Canada 2014 2 3 4 Agenda Dr. John Lefebre, M.D., FRCPC 1. TIA

More information

Current Updates & Challenges In Managing Diabetes in CVD

Current Updates & Challenges In Managing Diabetes in CVD Current Updates & Challenges In Managing Diabetes in CVD Preventive Cardiovascular Conference 2016 Instituit Jantung Negara 12 th November 2016 Nor Azmi Kamaruddin Diabetes Clinic Department of Medicine

More information

Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012

Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,

More information

Comorbidities of migraine

Comorbidities of migraine Comorbidities of migraine Jasna Zidverc Trajković Headache center Comorbidity is greater than coincidental association of two (or more) conditions in the same individual. Feinstein 1963 Migraine has been

More information

PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars

PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was

More information

MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?

MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE

More information

Reversible cerebral vasoconstriction syndrome with concurrent bilateral carotid artery dissection

Reversible cerebral vasoconstriction syndrome with concurrent bilateral carotid artery dissection Brief Report Reversible cerebral vasoconstriction syndrome with concurrent bilateral carotid artery dissection Cephalalgia 33(7) 491 495! International Headache Society 2013 Reprints and permissions: sagepub.co.uk/journalspermissions.nav

More information

A Clinical Context Report

A Clinical Context Report Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and

More information

Cryptogenic Strokes: Evaluation and Management

Cryptogenic Strokes: Evaluation and Management Cryptogenic Strokes: Evaluation and Management 77 yo man with hypertension and hyperlipidemia developed onset of left hemiparesis and right gaze preference, last seen normal at 10:00 AM Brought to ZSFG

More information

CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS)

CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS) CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS) Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Germany CGRP, Monoclonal Antibodies and Small Molecules

More information

The Strategic Reperfusion Early After STEMI study Implications for clinical practice

The Strategic Reperfusion Early After STEMI study Implications for clinical practice The Strategic Reperfusion Early After STEMI study Implications for clinical practice Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization and Interventional

More information

Myocardial Injury after Noncardiac Surgery (MINS): What is it and what can we do to help patients suffering this event? PJ Devereaux, MD, PhD

Myocardial Injury after Noncardiac Surgery (MINS): What is it and what can we do to help patients suffering this event? PJ Devereaux, MD, PhD Myocardial Injury after Noncardiac Surgery (MINS): What is it and what can we do to help patients suffering this event? PJ Devereaux, MD, PhD Disclosure Member of research group with policy of not accepting

More information

SickKids Research Institute: List of Funders

SickKids Research Institute: List of Funders SickKids Research Institute: List of Funders 2009-2010 Agency Funding $ Agency Funding $ 3M Pharmaceuticals 2,901 International Council on Amino Acid Science 80,800 Abbott Diagnostics 6,639 International

More information

Patent Foramen Ovale: Diagnosis and Treatment

Patent Foramen Ovale: Diagnosis and Treatment Patent Foramen Ovale: Diagnosis and Treatment Anthony DeMaria Judy and Jack White Chair in Cardiology University of California, San Diego At one time or another a Grantee, Sponsored Speaker or Ad-hoc Consultant

More information

What s New in the AF Guidelines

What s New in the AF Guidelines Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What

More information

Decline in CV-Mortality

Decline in CV-Mortality Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer

More information

Faculty Disclosures. Learning Objectives

Faculty Disclosures. Learning Objectives WWW.AMERICANHEADACHESOCIETY.ORG Pathophysiology Content developed by: Andrew C. Charles, MD, FAHS, Peter J. Goadsby, MD, PhD, FAHS Donna Gutterman, PharmD Faculty Disclosures ANDREW C. CHARLES, MD, FAHS

More information

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:

More information

CURRICULUM VITAE Intern in Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA

CURRICULUM VITAE Intern in Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA Bruce D. Kohrman, M.D. 12305 SW 69 th Place Miami, Florida 33156 Telephone: (305) 903-8678 Fax: (305) 661-1672 CURRICULUM VITAE EDUCATION 1977 - B.S. Stanford University, Stanford, CA 1982 - M.D. Case

More information

Atrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto

Atrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto

More information

Improving Door-to-Needle Times in Acute Ischemic Stroke: Principal Results from the Target: Stroke Initiative

Improving Door-to-Needle Times in Acute Ischemic Stroke: Principal Results from the Target: Stroke Initiative Improving Door-to-Needle Times in Acute Ischemic Stroke: Principal Results from the Target: Stroke Initiative Gregg C. Fonarow MD, Xin Zhao MS, Eric E. Smith MD, MPH, Jeffrey L. Saver MD, Mathew J. Reeves

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/44385 holds various files of this Leiden University dissertation. Author: Ayata, C. Title: Spreading depolarizations : the missing link between mirgraine

More information

Acute and chronic treatments

Acute and chronic treatments 21st Annual Meeting of the Swiss Stroke Society Lausanne, 11 January 2018 Vasculitis and stroke : Acute and chronic treatments Pr Mathieu ZUBER Service de Neurologie et NeuroVasculaire Groupe Hospitalier

More information

Venous thrombosis in unusual sites

Venous thrombosis in unusual sites Venous thrombosis in unusual sites Walter Ageno Department of Medicine and Surgery University of Insubria Varese Italy Disclosures Employment Research support Scientific advisory board Consultancy Speakers

More information

Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14

Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Disclosures Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance

More information